BusinessActinium’s Chief Medical Officer, Dr. Mark Berger, to Present Talk Titled, Iomab-B: Radiolabeled CD45 at the 3rd Annual Expert Forum on Acute Leukemias and Myeloproliferative NeoplasmsBy Nasdaq OMXJan 24, 2017, 12:01 PM UTC
BusinessActinium’s Chief Medical Officer, Dr. Mark Berger, to Present Talk Titled, Iomab-B: Radiolabeled CD45 at the 3rd Annual Expert Forum on Acute Leukemias and Myeloproliferative NeoplasmsBy Nasdaq OMXJan 24, 2017, 12:01 PM UTC
BusinessActinium Announces Participation in Three Upcoming Hematology EventsBy Nasdaq OMXJan 20, 2017, 12:00 PM UTC
BusinessActinium Strengthens Executive Team and Enhances Clinical Development Capabilities with the Appointment of Dr. Mark Berger as Chief Medical OfficerBy Nasdaq OMXJan 18, 2017, 1:01 PM UTC
BusinessActinium Strengthens Executive Team and Enhances Clinical Development Capabilities with the Appointment of Dr. Mark Berger as Chief Medical OfficerBy Nasdaq OMXJan 18, 2017, 1:01 PM UTC
BusinessActinium Pharmaceuticals to Present at 9th Annual Biotech Showcase™ 2017 ConferenceBy Nasdaq OMXJan 10, 2017, 12:00 PM UTC
BusinessActinium Pharmaceuticals to Present at 9th Annual Biotech Showcase™ 2017 ConferenceBy Nasdaq OMXJan 4, 2017, 12:00 PM UTC
BusinessActinium Pharmaceuticals Appoints Jeannine Larrieux, Ph.D. as Director of Analytical Development to Support BLA and IND Enabling Analytical Studies for Current and Future Clinical ProgramsBy Nasdaq OMXDec 19, 2016, 12:00 PM UTC
